The Company incurred aggregate restructuring charges of approximately $32.6 million for the three months ended June 30, 2025. Restructuring charges primarily consisted of employee termination benefits in connection with the reduction in force announced in June 2025 and contract termination costs primarily associated with exit fees relating to third-party manufacturers that were contracted for commercial supplies of birtamimab. Employee termination benefits include severance costs, employee-related benefits, and non-cash share-based compensation expense related to the acceleration of the vesting of certain stock options. Charges and other costs related to the restructuring plan are presented as restructuring costs in the Condensed Consolidated Statements of Operations. Substantially all of the cash payments are expected to be paid out by the end of the fourth quarter of 2025. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the restructuring plan.


	Restructuring Liability
	Termination Benefits		Contract Termination Costs		Other		Total
Balance at March 31, 2025	$	—	$	—	$	—	$	—
Restructuring Charges	18,342		14,097		170		32,609
Adjustment for non-cash charges	(2,081)		(37)		(161)		(2,279)
Reduction for cash payments	—		—		—		—
Foreign Exchange	—		—		—		—
Balance at June 30, 2025	$	16,261	$	14,060	$	9	$	30,330

The total amount expected to be incurred in connection with the restructuring plan is $32.6 million. The restructuring liability is included in current liabilities on the Condensed Consolidated Balance Sheets as of June 30, 2025.